

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

**Company** 2023/05/26 22:00:00

**Price**  
**298.66**  
USD

**Difference**  0.51%(1.53)



**Contact Details**

BIOGEN INC. Tel: +1-617-679-2000  
 -- Fax: +  
 225 Binney Street Web: <http://www.biogen.com>  
 02142 Cambridge E-mail: [info@biogen.com](mailto:info@biogen.com)

## Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	9,791,200,000		7,856,500,000		6,887,100,000	
<b>Common stock capital</b>		100,000		100,000		100,000
<b>Fixed assets</b>	14,762,900,000		16,020,800,000		17,731,800,000	
<b>Equity capital of a company</b>		13,388,400,000		10,959,700,000		10,686,100,000
<b>Cash and cash equivalents</b>	3,419,300,000		2,261,400,000		1,331,200,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		3,272,800,000		4,298,200,000		3,742,200,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		7,892,900,000		8,619,400,000		10,190,600,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		944,200,000		1,320,500,000		1,329,600,000
<b>Total assets</b>	24,554,100,000	24,554,100,000	23,877,300,000	23,877,300,000	24,618,900,000	24,618,900,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	8,725	9,610	9,100
<b>Equity ratio</b>	54.49%	46.17%	43.35%
<b>Debt-equity ratio</b>	83.53%	116.61%	130.69%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	17.62%	3.01%	19.66%

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

## Income statement

	2022	2021	2020
<b>Turnover</b>	9,433,400,000	10,402,400,000	12,356,000,000
<b>Net income</b>	3,046,900,000	1,556,100,000	4,000,600,000
<b>EBIT</b>	3,511,981,500	1,887,473,250	4,938,986,250
<b>Operating income before taxes</b>	3,591,800,000	1,745,200,000	5,047,500,000
<b>Cash Flow</b>	1,384,300,000	3,639,900,000	4,229,800,000
<b>Net interest income</b>	-174,400,000	-278,900,000	-249,000,000
<b>Research and development expenses</b>	1,958,700,000	2,265,900,000	3,789,000,000
<b>Income taxes</b>	632,800,000	52,500,000	992,300,000
<b>Result from investments in subsidiaries, associates and other</b>	2,600,000	34,900,000	5,300,000
<b>Revenues per employee</b>	1,008,212	1,009,390	1,266,151

## Board of Directors

## Members of Management Board

Stelios Papadopoulos	Chairman of Board of Directors
Alexander Denner	Member of Board of Directors
Eric Rowinsky	Member of Board of Directors
Maria Freire	Member of Board of Directors
Richard Mulligan	Member of Board of Directors
Stephen Sherwin	Member of Board of Directors
Caroline Dorsa	Member of Board of Directors
Jesus Mantas	Member of Board of Directors
William Hawkins	Member of Board of Directors
William Jones	Member of Board of Directors
Michel Vounatsos	Chairman of Managing Board
Ginger Gregory	Member of Executive Committee
Alphonse Galdes	Member of Executive Committee
Michael McDonnell	Member of Executive Committee
Rachid Izzar	Member of Executive Committee
Susan H. Alexander	Member of Executive Committee